Health News // 4 hours ago
Experimental drug vorasidenib shows promise for treating glioma brain tumors
The oral drug vorasidenib nearly tripled progression-free survival in patients with grade 2 gliomas compared to placebo, nearly 28 months versus 11 months, according to a recent study.